Product Name
Cytochrome P450 4V2 (CYP4V2), Polyclonal Antibody
Full Product Name
Anti-Cytochrome P450 4V2 Antibody
Product Gene Name
anti-CYP4V2 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q6ZWL3
Specificity
Recognizes endogenous levels of Cytochrome P450 4V2 protein.
Purity/Purification
Purified by immunogen affinity chromatography.
Form/Format
Liquid in 0.42% Potassium Phosphate, 0.87% Sodium Chloride, pH 7.3, 30% Glycerol, and 0.01% Sodium Azide.
Immunogen
KLH-conjugated synthetic peptide encompassing a sequence within the center region of human Cytochrome P450 4V2.
Preparation and Storage
Upon delivery aliquot and store at-20 degree C for one year. Avoid freeze/thaw cycles.
Other Notes
Small volumes of anti-CYP4V2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-CYP4V2 antibody
Rabbit polyclonal antibody to Cytochrome P450 4V2
Applications Tested/Suitable for anti-CYP4V2 antibody
Western Blot (WB), Immunohistochemistry (IHC)
Application Notes for anti-CYP4V2 antibody
WB: 1:500-1:1000
IHC: 1:50-1:100
Western Blot (WB) of anti-CYP4V2 antibody
Western blot analysis of Cytochrome P450 4V2 expression in U87MG (A) whole cell lysates.
Immunohistochemistry (IHC) of anti-CYP4V2 antibody
Immunohistochemical analysis of Cytochrome P450 4V2 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
NCBI/Uniprot data below describe general gene information for CYP4V2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_997235.3
[Other Products]
NCBI GenBank Nucleotide #
NM_207352.3
[Other Products]
UniProt Primary Accession #
Q6ZWL3
[Other Products]
UniProt Secondary Accession #
Q6ZTM4; B7U6W2[Other Products]
UniProt Related Accession #
Q6ZWL3[Other Products]
Molecular Weight
58,166 Da
NCBI Official Full Name
cytochrome P450 4V2
NCBI Official Synonym Full Names
cytochrome P450 family 4 subfamily V member 2
NCBI Official Symbol
CYP4V2 [Similar Products]
NCBI Official Synonym Symbols
BCD; CYP4AH1
[Similar Products]
NCBI Protein Information
cytochrome P450 4V2
UniProt Protein Name
Cytochrome P450 4V2
UniProt Synonym Protein Names
Docosahexaenoic acid omega-hydroxylase CYP4V2Curated (EC:1.14.14.791 PublicationManual assertion based on experiment iniRef.7"CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of omega-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant."Nakano M., Kelly E.J., Wiek C., Hanenberg H., Rettie A.E.Mol. Pharmacol. 82:679-686(2012) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, CHARACTERIZATION OF VARIANT BCD PRO-331.
Protein Family
Cytochrome
UniProt Gene Name
CYP4V2 [Similar Products]
NCBI Summary for CYP4V2
This gene encodes a member of the cytochrome P450 hemethiolate protein superfamily which are involved in oxidizing various substrates in the metabolic pathway. It is implicated in the metabolism of fatty acid precursors into n-3 polyunsaturated fatty acids. Mutations in this gene result in Bietti crystalline corneoretinal dystrophy. [provided by RefSeq, Jul 2008]
UniProt Comments for CYP4V2
Omega-hydroxylase that oxidizes medium-chain saturated fatty acids and polyunsaturated omega-3 fatty acids, and which plays a role in fatty acid and steroid metabolism in the eye (PubMed:19661213, PubMed:22772592). Catalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. The substrate specificity is higher for myristate > laurate > palmitate (C14>C16>C12) (PubMed:19661213). Acts as a polyunsaturated omega-3 fatty acids hydroxylase by mediating oxidation of docosahexaenoate (DHA) to 22-hydroxydocosahexaenoate (PubMed:22772592). Also produces some 21-hydroxydocosahexaenoate. Also converts eicosapentaenoate (EPA) to 20-hydroxyeicosapentaenoate (20-OH-EPA) (PubMed:22772592).
Research Articles on CYP4V2
1. This is the first report of a homozygous R400C mutation in CYP4V2 with protein modelling showing high likelihood of enzyme dysfunction. The comprehensive long-term clinical follow-up provides insight into disease progression and highlights possible anti-inflammatory modulation of disease severity.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
